Biparatopic antibodies: therapeutic applications and prospects

Biparatopic antibodies: therapeutic applications and prospects

Biparatopic antibodies (bpAbs) bind distinct, non-overlapping epitopes on an antigen. This unique binding mode enables new mechanisms of action beyond monospecific and bispecific antibodies (bsAbs) that can make bpAbs effective therapeutics for various indications, including oncology and infectious...

Full description

Saved in:

Bibliographic Details
Main Authors:	David L. Niquille, Kyle M. Fitzgerald, Nimish Gera
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	mAbs
Subjects:	Antibody engineering antibody-drug conjugates biparatopic antibodies bispecific antibodies chimeric antigen receptors infectious disease
Online Access:	https://www.tandfonline.com/doi/10.1080/19420862.2024.2310890
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET
by: Andreas Evers, et al.
Published: (2024-12-01)

Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows
by: Caitlin Fawcett, et al.
Published: (2024-12-01)

Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01)

Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity
by: Jeremy Loyau, et al.
Published: (2025-12-01)

Electrostatic properties of human germlines and biodistribution of small biologics
by: Leticia Maria De Souza Cordeiro, et al.
Published: (2024-12-01)

Editorial: The immune response to therapeutic antibodies
by: Michael G. Tovey, et al.
Published: (2025-02-01)

Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
by: Masaud Shah, et al.
Published: (2025-01-01)

Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces
by: W. van der Wulp, et al.
Published: (2024-12-01)

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release
by: John S. Schardt, et al.
Published: (2024-12-01)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
by: Ammelie Svea Boje, et al.
Published: (2024-12-01)

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy
by: Gerhard Frey, et al.
Published: (2024-12-01)

A tailored lectin microarray for rapid glycan profiling of therapeutic monoclonal antibodies
by: Shen Luo, et al.
Published: (2024-12-01)

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
by: Amelia C. McCue, et al.
Published: (2024-12-01)

Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma
by: Charissa Wijnands, et al.
Published: (2025-01-01)

Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies
by: Ugochi Ebinama, et al.
Published: (2025-01-01)

RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties
by: Barnabas Nyesiga, et al.
Published: (2024-12-01)

Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024-12-01)

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies
by: Wen-Ting K. Tsai, et al.
Published: (2024-12-01)

Bispecific antibodies and CLEM: an analytical approach to advanced cell imaging for therapeutic strategies
by: Han-ul Kim, et al.
Published: (2025-01-01)

Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy
by: Kun Du, et al.
Published: (2025-02-01)

Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge
by: M. Biddle, et al.
Published: (2024-12-01)

A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs
by: Itzel Condado-Morales, et al.
Published: (2024-12-01)

T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics
by: Ruoxuan Sun, et al.
Published: (2024-12-01)

BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA
by: Ugo Testa, et al.
Published: (2024-08-01)

Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer
by: Xiaojie Chu, et al.
Published: (2024-12-01)

Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
by: Katy Lloyd, et al.
Published: (2025-02-01)

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies
by: Aimee E. Mattei, et al.
Published: (2024-12-01)

Identification of rare anti-f alloantibody in a tertiary care center in India
by: Gunjan Bhardwaj, et al.
Published: (2024-01-01)

Can antibodies be “vegan”? A guide through the maze of today’s antibody generation methods
by: Stefan Dübel
Published: (2024-12-01)

Expression Analysis of Heavy-Chain-Only Antibodies in Cloudy Catshark and Japanese Bullhead Shark
by: Reo Uemura, et al.
Published: (2025-01-01)

Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo
by: Zheng Wang, et al.
Published: (2024-12-01)

Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer
by: Riqing Huang, et al.
Published: (2025-01-01)

Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors
by: Geoff Hale, et al.
Published: (2024-12-01)

Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
by: Zhijuan Ai, et al.
Published: (2025-01-01)

Do antibody CDR loops change conformation upon binding?
by: Chu’nan Liu, et al.
Published: (2024-12-01)

Rapid depletion of “catch-and-release” anti-ASGR1 antibody in vivo
by: Siva Charan Devanaboyina, et al.
Published: (2024-12-01)

Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors
by: Geoff Hale, et al.
Published: (2024-12-01)

Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
by: Hanghang Ma, et al.
Published: (2025-02-01)

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
by: Anna-Maria Lazaratos, et al.
Published: (2024-12-01)

Current issues with antibody-conjugated lipid nanoparticles
by: Aayush
Published: (2025-02-01)